Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders

This new high dose Wegovy data could help support Novo Nordisk in its bid to claw back market share taken by Eli Lilly in the obesity space. This data could help support Novo in its bid to claw back market share taken by Eli Lilly in the obesity space. A sub-analysis reveals that Novo Nordisk’s Wegovy HD can prompt weight loss of up to 27.7% in early repsonders. Credit: Visual Generation / Shutterstock.com. Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug, Wegovy (semaglutide), can prompt stronger weight loss in patients,…

Source: Clinical Trials Arena